Best Medication for Erectile Dysfunction in a 74-Year-Old Man
An FDA-approved oral phosphodiesterase type 5 inhibitor (PDE5i)—sildenafil, tadalafil, vardenafil, or avanafil—is the best first-line medication for this patient, with all four agents showing similar efficacy in elderly men. 1
Primary Treatment Recommendation
The 2018 AUA Guideline provides a Strong Recommendation (Evidence Level: Grade B) that men with ED should be offered an FDA-approved oral PDE5i as first-line therapy unless contraindicated 1. This recommendation applies equally to elderly patients, including those 74 years old.
Efficacy in Elderly Men
All four FDA-approved PDE5i agents demonstrate comparable effectiveness:
Sildenafil: In elderly men ≥65 years, 80% of men <65 years reported improved erections, 69% of men aged 65-74 years, and 59% of men ≥75 years 2. Your 74-year-old patient falls into the middle category with expected ~69% response rate.
Tadalafil: Demonstrated significant improvement in elderly men (mean age 71.6 years), with 40% achieving normal erectile function and 81% reporting improved erections 3. Notably, tadalafil maintained efficacy up to 36 hours post-dose in elderly patients.
Vardenafil and Avanafil: Show similar efficacy profiles across age groups 1
Choosing Between PDE5i Agents
While efficacy is equivalent, side effect profiles differ slightly 1:
- Lowest dyspepsia: Avanafil
- Lowest flushing: Tadalafil
- Lowest myalgia: Vardenafil and avanafil
Practical consideration: Tadalafil offers the advantage of longer duration (up to 36 hours), which may reduce performance anxiety and allow more spontaneity—particularly valuable for elderly patients 3.
Critical Implementation Steps
1. Cardiovascular Risk Assessment (MANDATORY)
Before prescribing any PDE5i, assess cardiovascular fitness for sexual activity 1, 4. ED is as strong a predictor of future cardiac events as cigarette smoking or family history of MI 1.
Absolute contraindications:
- Current nitrate therapy or nitric oxide donors
- Severe cardiac failure
- Unstable angina
- Recent stroke or myocardial infarction
2. Proper Patient Education (Critical for Success)
Incorrect use accounts for a large percentage of treatment failures 1. Specifically instruct:
- Sexual stimulation is necessary—the medication does not work without it
- Timing matters: Take 1 hour before sexual activity (sildenafil, vardenafil); tadalafil can be taken 30 minutes to 12 hours before
- Avoid large meals: High-fat meals reduce absorption and efficacy
- Multiple trials required: At least 4-8 attempts needed before declaring treatment failure 1
3. Dose Titration Strategy
Start with standard dosing, then titrate 1:
- Sildenafil: Start 50 mg, adjust to 25-100 mg
- Tadalafil: Start 10 mg, adjust to 5-20 mg (or 2.5-5 mg daily dosing)
- Vardenafil: Start 10 mg, adjust to 5-20 mg
- Avanafil: Start 100 mg, adjust to 50-200 mg
Important caveat for elderly patients: In men with mild-to-moderate hepatic/renal impairment (common at age 74), start with lower doses due to delayed metabolism 1.
Special Considerations for This Age Group
Testosterone Screening
Check morning testosterone level 1. If testosterone deficiency is present (<230-350 ng/dL), combining PDE5i with testosterone therapy is more effective than PDE5i alone (Moderate Recommendation; Evidence Level: Grade C) 1. However, testosterone alone is NOT effective monotherapy for ED.
Comorbidity Impact
Elderly men often have conditions that reduce PDE5i response 1:
- Diabetes: Significantly reduces efficacy 5—only 65.7% response in elderly diabetics vs 89.1% in younger men
- Post-prostatectomy: More severe ED at baseline, less robust response 1
Common Pitfalls to Avoid
- Premature treatment failure declaration: Ensure patient has attempted medication at least 4-8 times with proper technique before switching agents
- Ignoring cardiovascular risk: ED diagnosis is an opportunity to address systemic cardiovascular disease 1, 4
- Not checking for drug interactions: Review for nitrates, alpha-blockers (may cause hypotension), and CYP3A4 inhibitors
- Overlooking testosterone deficiency: This reduces PDE5i efficacy 1
Alternative if PDE5i Fails
If PDE5i therapy fails after proper trials and dose optimization, second-line options include 1:
- Vacuum erection devices (VED)
- Intracavernosal injections
- Intraurethral alprostadil
However, ensure PDE5i failure is genuine (proper use, adequate trials, optimal dosing, testosterone optimization if needed) before advancing to second-line therapy.